| AASLD

Thoracic epidural analgesia in donor hepatectomy: An analysis

Read more about Thoracic epidural analgesia in donor hepatectomy: An analysis

Archna Koul, Deepanjali Pant, Swetha Rudravaram, Jayashree Sood – 2 December 2017 – The purpose of this study is to analyze whether supplementation of general anesthesia (GA) with thoracic epidural analgesia (TEA) for right lobe donor hepatectomy is a safe modality of pain relief in terms of changes in postoperative coagulation profile, incidence of epidural catheter–related complications, and timing of removal of epidural catheter. Retrospective analysis of the record of 104 patients who received TEA for right lobe donor hepatectomy was done.

The short‐term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct‐acting antivirals: An ERCHIVES study

Read more about The short‐term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct‐acting antivirals: An ERCHIVES study

Darrick K. Li, Yanjie Ren, Daniel S. Fierer, Stephanie Rutledge, Obaid S. Shaikh, Vincent Lo Re, Tracey Simon, Abdul‐Badi Abou‐Samra, Raymond T. Chung, Adeel A. Butt – 2 December 2017 – Recent studies have reported higher rates of hepatocellular carcinoma (HCC) in individuals treated with direct‐acting antivirals (DAAs). However, making definitive conclusions has been challenging because of the heterogeneous populations and methodologies of these reports.

Hepatitis C transmission from seropositive, nonviremic donors to non–hepatitis C liver transplant recipients

Read more about Hepatitis C transmission from seropositive, nonviremic donors to non–hepatitis C liver transplant recipients

Khurram Bari, Keith Luckett, Tiffany Kaiser, Tayyab Diwan, Madison Cuffy, Michael R. Schoech, Kamran Safdar, Jason T. Blackard, Senu Apewokin, Flavio Paterno, Kenneth E. Sherman, Stephen D. Zucker, Nadeem Anwar, Shimul A. Shah – 2 December 2017 – Breakthroughs in hepatitis C virus (HCV) treatment and rising rates of intravenous drug use have led to an increase in the number of organ donors who are HCV antibody–positive but serum nucleic acid test (NAT)–negative. The risk of HCV transmission from the liver grafts of these donors to recipients is unknown.